موافقات الدواء

is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
• in combination with an aromatase inhibitor
• in combination with fulvestrant in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Treatment with IBRANCE should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.